Abstract
Radiopharmaceutical therapy represents a growing treatment modality in prostate cancer, and this chapter will focus on how Artificial Intelligence (AI) can be applied to preclinical development of this treatment paradigm. The study, presents a Multi-Modal Attention Enhanced Neural Network (MAENN) to integrate disparate data types—imaging, molecular and pharmacokinetics—to improve predictions of therapy efficacy, determination of optimal dose and the identification of specific biomarkers. Compared to a number of conventional models such as SVMs and CNNs, MAENN maintains the highest accuracy in prediction, sensitivity and data integration capabilities. Although issues like data quality and computational complexity remain, the chapter also describes the scalability, potential for real-time applications, and future applications of MAENN in other cancer therapies, contributing towards personalizing treatment strategies in order to pave the way for precision oncology.

This publication has 13 references indexed in Scilit: